Drug: Bunavail
BUNAVAIL (buprenorphine and naloxone) buccal film is a citrus flavored oral transmucosal form of buprenorphine and naloxone, intended for application to the buccal mucosa. Each dose unit is a yellow rectangular film, with ink marking on the mucoadhesive side. The film adheres upon contact with the moist buccal mucosa. BUNAVAIL contains buprenorphine HCl, a mu-opioid receptor partial agonist and a kappa-opioid receptor antagonist, and naloxone HCl dihydrate, an opioid receptor antagonist, at a ratio of ~6:1 (ratio of free bases). It is available in three strengths: 2.1 mg buprenorphine with 0.3 mg naloxone in a 2.2 cm² film; 4.3 mg buprenorphine with 0.7 mg naloxone in a 4.4 cm² film; and 6.3 mg buprenorphine with 1 mg naloxone in a 6.5 cm² film. Each film also contains carboxymethylcellulose sodium, citric acid, citrus blend flavor, dibasic sodium phosphate, blue ink, hydroxyethyl cellulose, hydroxypropyl cellulose, methylparaben, monobasic sodium phosphate, polycarbophil, propylene glycol, propylparaben, yellow iron oxide, sodium benzoate, sodium hydroxide, sodium saccharin, vitamin E acetate, and purified water. The blue ink contains FD&C blue #1, ethanol, purified shellac, acetone, ammonium hydroxide and water. Chemically, buprenorphine HCl, USP is 6,14-Ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-α-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-α-methyl-, hydrochloride, [5α,7α(S)]. It has the following chemical structure: Buprenorphine HCl has the molecular formula C29H41NO4 • HCl and the molecular weight is 504.10. It is a white or off-white crystalline powder, sparingly soluble in water, freely soluble in methanol, soluble in alcohol, and practically insoluble in cyclohexane. Chemically, naloxone HCl dihydrate, USP is morphinan-6-one, 4,5-epoxy-3,14-dihydroxy-17-(2-propenyl)-, hydrochloride, (5α)-, dihydrate. It has the following chemical structure: Naloxone hydrochloride dihydrate has the molecular formula C19H21NO4 • HCl • 2H2O and the molecular weight is 399.87. It is a white to slightly off-white powder, and is freely soluble in water, soluble in alcohol, and practically insoluble in toluene and ether. Last reviewed on RxList: 6/20/2014
This monograph has been modified to include the generic and brand name in many instances.
This monograph has been modified to include the generic and brand name in many instances.
Source: http://www.rxlist.com
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Adverse Events In Clinical Trials The safety of BUNAVAIL buccal film is supported by clinical trials using buprenorphine and naloxone sublingual tablets, and other trials using buprenorphine tablets and buprenorphine sublingual solutions, as well as an open-label study in 249 patients treated with BUNAVAIL buccal film. In total, safety data from clinical studies are available from over 3000 opioid-dependent subjects exposed to buprenorphine at doses in the range used in the treatment of opioid addiction. Few differences in the adverse event profile were noted among buprenorphine and naloxone sublingual tablets, buprenorphine sublingual tablets and a buprenorphine ethanolic sublingual solution. The safety and tolerability of BUNAVAIL was evaluated in a 12-week clinical study of BUNAVAIL in 249 opioid-dependent subjects stabilized on buprenorphine and naloxone sublingual tablet or film dosages of 8-32 mg/day. The following adverse reactions were reported to occur by at least 5% of patients in a 12-week study with BUNAVAIL: drug withdrawal syndrome, lethargy and headache. The adverse reactions listed below represent those that were reported by > 1%, but less than 5% of patients from the 12-week clinical trial while receiving BUNAVAIL. Events are classified by system organ class.
Body System/ Adverse Event (COSTART) Terminology Buprenorphine/naloxone sublingual tablets 16/4 mg/day
N=107
n(%) Placebo
N=107
n (%) Body as a Whole Asthenia 7(6.5%) 7(6.5%) Chills 8(7.5%) 8(7.5%) Headache 39(36.4%) 24(22.4%) Infection 6(5.6%) 7(6.5%) Pain 24(22.4%) 20(18.7%) Pain abdomen 12 (11.2%) 7(6.5%) Pain back 4(3.7%) 12 (11.2%) Withdrawal syndrome 27(25.2%) 40(37.4%) Cardiovascular System Vasodilation 10(9.3%) 7(6.5%) Digestive System Constipation 13(12.1%) 3(2.8%) Diarrhea 4(3.7%) 16(15.0%) Nausea 16(15.0%) 12 (11.2%) Vomiting 8(7.5%) 5(4.7%) Nervous System Insomnia 15(14.0%) 17(15.9%) Respiratory System Rhinitisnai 5(4.7%) 14(13.1%) Skin and Appendages Sweating 15(14.0%) 11(10.3%) The adverse event profile of buprenorphine was also characterized in the dose-controlled study of buprenorphine solutions, over a range of doses in four months of treatment. Table 2 shows adverse events reported by at least 5% of subjects in any dose group in the dose-controlled study. Table 2 : Adverse Events ( > 5%) by Body System and Treatment Group in a 16-week Study
Body System /Adverse Event (COSTART Terminology) Buprenorphine Dose* Very Low*
(N=184)
n (%) Low*
(N=180)
n (%) Moderate*
(N=186)
n (%) High*
(N=181)
n (%) Total*
(N=731)
n (%) Body as a Whole Abscess 9(5%) 2 (1%) 3(2%) 2 (1%) 16(2%) Asthenia 26(14%) 28(16%) 26(14%) 24(13%) 104(14%) Chills 11 (6%) 12(7%) 9(5%) 10 (6%) 42(6%) Fever 7(4%) 2 (1%) 2 (1%) 10 (6%) 21(3%) Flu Syndrome 4(2%) 13(7%) 19(10%) 8(4%) 44(6%) Headache 51(28%) 62(34%) 54(29%) 53(29%) 220(30%) Infection 32(17%) 39(22%) 38(20%) 40(22%) 149(20%) Injury Accidental 5(3%) 10 (6%) 5(3%) 5(3%) 25(3%) Pain 47(26%) 37(21%) 49(26%) 44(24%) 177(24%) Pain Back 18(10%) 29(16%) 28(15%) 27(15%) 102(14%) Withdrawal Syndrome 45(24%) 40(22%) 41(22%) 36(20%) 162(22%) Digestive System Constipation 10(5%) 23(13%) 23(12%) 26(14%) 82(11%) Diarrhea 19(10%) 8(4%) 9(5%) 4(2%) 40(5%) Dyspepsia 6(3%) 10 (6%) 4(2%) 4(2%) 24(3%) Nausea 12(7%) 22 (12%) 23(12%) 18(10%) 75(10%) Vomiting 8(4%) 6(3%) 10(5%) 14(8%) 38(5%) Nervous System Anxiety 22 (12%) 24(13%) 20 (11%) 25(14%) 91(12%) Depression 24(13%) 16(9%) 25(13%) 18(10%) 83(11%) Dizziness 4(2%) 9(5%) 7(4%) 11 (6%) 31(4%) Insomnia 42(23%) 50(28%) 43(23%) 51(28%) 186(25%) Nervousness 12(7%) 11 (6%) 10(5%) 13(7%) 46(6%) Somnolence 5(3%) 13(7%) 9(5%) 11 (6%) 38(5%) Respiratory System Cough Increase 5(3%) 11 (6%) 6(3%) 4(2%) 26(4%) Pharyngitis 6(3%) 7(4%) 6(3%) 9(5%) 28(4%) Rhinitis 27(15%) 16(9%) 15(8%) 21 (12%) 79(11%) Skin and Appendages Sweat 23(13%) 21 (12%) 20 (11%) 23(13%) 87(12%) Special Senses Runny Eyes 13(7%) 9(5%) 6(3%) 6(3%) 34(5%) *Sublingual solution. Doses in this table cannot necessarily be delivered in film form, but for comparison purposes: “very low” dose (1 mg solution) would be less than a tablet dose of 2 mg; “low” dose (4 mg solution) approximates a 6 mg tablet dose; “moderate” dose (8 mg solution) approximates a 12 mg tablet dose; “high” dose (16 mg solution) approximates a 24 mg tablet dose. Read the Bunavail (buprenorphine and naloxone buccal film) Side Effects Center for a complete guide to possible side effectsLearn More »
- General disorders and administration site conditions: fatigue and chills
- Nervous system disorders: somnolence
- Psychiatric disorders: drug dependence and insomnia
- Gastrointestinal disorders: constipation and oral mucosal erythema
- Respiratory, thoracic and mediastinal disorders: rhinorrhea
- Skin and subcutaneous tissue disorders: hyperhidrosis
Body System/ Adverse Event (COSTART) Terminology Buprenorphine/naloxone sublingual tablets 16/4 mg/day
N=107
n(%) Placebo
N=107
n (%) Body as a Whole Asthenia 7(6.5%) 7(6.5%) Chills 8(7.5%) 8(7.5%) Headache 39(36.4%) 24(22.4%) Infection 6(5.6%) 7(6.5%) Pain 24(22.4%) 20(18.7%) Pain abdomen 12 (11.2%) 7(6.5%) Pain back 4(3.7%) 12 (11.2%) Withdrawal syndrome 27(25.2%) 40(37.4%) Cardiovascular System Vasodilation 10(9.3%) 7(6.5%) Digestive System Constipation 13(12.1%) 3(2.8%) Diarrhea 4(3.7%) 16(15.0%) Nausea 16(15.0%) 12 (11.2%) Vomiting 8(7.5%) 5(4.7%) Nervous System Insomnia 15(14.0%) 17(15.9%) Respiratory System Rhinitisnai 5(4.7%) 14(13.1%) Skin and Appendages Sweating 15(14.0%) 11(10.3%) The adverse event profile of buprenorphine was also characterized in the dose-controlled study of buprenorphine solutions, over a range of doses in four months of treatment. Table 2 shows adverse events reported by at least 5% of subjects in any dose group in the dose-controlled study. Table 2 : Adverse Events ( > 5%) by Body System and Treatment Group in a 16-week Study
Body System /Adverse Event (COSTART Terminology) Buprenorphine Dose* Very Low*
(N=184)
n (%) Low*
(N=180)
n (%) Moderate*
(N=186)
n (%) High*
(N=181)
n (%) Total*
(N=731)
n (%) Body as a Whole Abscess 9(5%) 2 (1%) 3(2%) 2 (1%) 16(2%) Asthenia 26(14%) 28(16%) 26(14%) 24(13%) 104(14%) Chills 11 (6%) 12(7%) 9(5%) 10 (6%) 42(6%) Fever 7(4%) 2 (1%) 2 (1%) 10 (6%) 21(3%) Flu Syndrome 4(2%) 13(7%) 19(10%) 8(4%) 44(6%) Headache 51(28%) 62(34%) 54(29%) 53(29%) 220(30%) Infection 32(17%) 39(22%) 38(20%) 40(22%) 149(20%) Injury Accidental 5(3%) 10 (6%) 5(3%) 5(3%) 25(3%) Pain 47(26%) 37(21%) 49(26%) 44(24%) 177(24%) Pain Back 18(10%) 29(16%) 28(15%) 27(15%) 102(14%) Withdrawal Syndrome 45(24%) 40(22%) 41(22%) 36(20%) 162(22%) Digestive System Constipation 10(5%) 23(13%) 23(12%) 26(14%) 82(11%) Diarrhea 19(10%) 8(4%) 9(5%) 4(2%) 40(5%) Dyspepsia 6(3%) 10 (6%) 4(2%) 4(2%) 24(3%) Nausea 12(7%) 22 (12%) 23(12%) 18(10%) 75(10%) Vomiting 8(4%) 6(3%) 10(5%) 14(8%) 38(5%) Nervous System Anxiety 22 (12%) 24(13%) 20 (11%) 25(14%) 91(12%) Depression 24(13%) 16(9%) 25(13%) 18(10%) 83(11%) Dizziness 4(2%) 9(5%) 7(4%) 11 (6%) 31(4%) Insomnia 42(23%) 50(28%) 43(23%) 51(28%) 186(25%) Nervousness 12(7%) 11 (6%) 10(5%) 13(7%) 46(6%) Somnolence 5(3%) 13(7%) 9(5%) 11 (6%) 38(5%) Respiratory System Cough Increase 5(3%) 11 (6%) 6(3%) 4(2%) 26(4%) Pharyngitis 6(3%) 7(4%) 6(3%) 9(5%) 28(4%) Rhinitis 27(15%) 16(9%) 15(8%) 21 (12%) 79(11%) Skin and Appendages Sweat 23(13%) 21 (12%) 20 (11%) 23(13%) 87(12%) Special Senses Runny Eyes 13(7%) 9(5%) 6(3%) 6(3%) 34(5%) *Sublingual solution. Doses in this table cannot necessarily be delivered in film form, but for comparison purposes: “very low” dose (1 mg solution) would be less than a tablet dose of 2 mg; “low” dose (4 mg solution) approximates a 6 mg tablet dose; “moderate” dose (8 mg solution) approximates a 12 mg tablet dose; “high” dose (16 mg solution) approximates a 24 mg tablet dose. Read the Bunavail (buprenorphine and naloxone buccal film) Side Effects Center for a complete guide to possible side effectsLearn More »
Source: http://www.rxlist.com
BUNAVAIL buccal film is applied to the buccal mucosa as a single daily dose. BUNAVAIL buccal film should be used in patients who have been initially inducted using buprenorphine sublingual tablets. The difference in bioavailability of BUNAVAIL compared to SUBOXONE sublingual tablet requires a different dosage strength to be administered to the patient. A BUNAVAIL 4.2/0.7 mg buccal film provides equivalent buprenorphine exposure to a SUBOXONE 8/2 mg sublingual tablet. Medication should be prescribed in consideration of the frequency of visits. Provision of multiple refills is not advised early in treatment or without appropriate patient follow-up visits. Maintenance
- BUNAVAIL buccal film is indicated for maintenance treatment. The recommended target dosage of BUNAVAIL buccal film is 8.4/1.4 mg per day as a single daily dose.
- The dosage of BUNAVAIL buccal film should be progressively adjusted in increments/decrements of 2.1/0.3 mg buprenorphine/naloxone to a level that holds the patient in treatment and suppresses opioid withdrawal signs and symptoms.
- The maintenance dose of BUNAVAIL buccal film is generally in the range of 2.1/0.3 mg buprenorphine/naloxone to 12.6/2.1 mg buprenorphine/naloxone per day depending on the individual patient. Dosages higher than this have not been demonstrated to provide any clinical advantage.
- use the tongue to wet the inside of the cheek or rinse the mouth with water to moisten the area immediately before placement of BUNAVAIL;
- open the BUNAVAIL package immediately prior to use as indicated by the instructions;
- hold the BUNAVAIL film with clean, dry fingers with the text (BN2, BN4, or BN6) facing up;
- place the side of the BUNAVAIL film with the text (BN2, BN4, or BN6) against the inside of the cheek;
- press and hold the film in place for 5 seconds.
- Absence of medication toxicity
- Absence of medical or behavioral adverse effects
- Responsible handling of medications by the patient
- Patient's compliance with all elements of the treatment plan (including recovery-oriented activities, psychotherapy, and/or other psychosocial modalities)
- Abstinence from illicit drug use (including problematic alcohol and/or benzodiazepine use)
Source: http://www.rxlist.com
Cytochrome P-450 3A4 (CYP3A4) Inhibitors And Inducers Buprenorphine is metabolized to norbuprenorphine primarily by cytochrome CYP3A4; therefore, potential interactions may occur when BUNAVAIL buccal film is given concurrently with agents that affect CYP3A4 activity. The concomitant use of BUNAVAIL buccal film with CYP3A4 inhibitors (e.g., azole antifungals such as ketoconazole, macrolide antibiotics such as erythromycin, and HIV protease inhibitors) should be monitored and may require dose-reduction of one or both agents. The interaction of buprenorphine with CYP3A4 inducers has not been studied; therefore, it is recommended that patients receiving BUNAVAIL buccal films be monitored for signs and symptoms of opioid withdrawal if inducers of CYP3A4 (e.g., efavirenz, phenobarbital, carbamazepine, phenytoin, rifampicin) are co-administered [see CLINICAL PHARMACOLOGY]. Antiretrovirals Three classes of antiretroviral agents have been evaluated for CYP3A4 interactions with buprenorphine. Nucleoside reverse transcriptase inhibitors (NRTIs) do not appear to induce or inhibit the P450 enzyme pathway, thus no interactions with buprenorphine are expected. Nonnucleoside reverse transcriptase inhibitors (NNRTIs) are metabolized principally by CYP3A4. Efavirenz, nevirapine and etravirine are known CYP3A4 inducers whereas delaviridine is a CYP3A inhibitor. Significant pharmacokinetic interactions between NNRTIs (e.g., efavirenz and delavirdine) and buprenorphine have been shown in clinical studies, but these pharmacokinetic interactions did not result in any significant pharmacodynamics effects. It is recommended that patients who are on chronic buprenorphine treatment have their dose monitored if NNRTIs are added to their treatment regimen. Studies have shown some antiretroviral protease inhibitors (PIs) with CYP3A4 inhibitory activity (nelfinavir, lopinavir/ritonavir, ritonavir) have little effect on buprenorphine pharmacokinetic and no significant pharmacodynamic effects. Other PIs with CYP3A4 inhibitory activity (atazanavir and atazanavir/ritonavir) resulted in elevated levels of buprenorphine and norbuprenorphine and patients in one study reported increased sedation. Symptoms of opioid excess have been found in post-marketing reports of patients receiving buprenorphine and atazanavir with and without ritonavir concomitantly. Monitoring of patients taking buprenorphine and atazanavir with and without ritonavir is recommended, and dose reduction of buprenorphine may be warranted. Benzodiazepines There have been a number of post-marketing reports regarding coma and death associated with the concomitant use of buprenorphine and benzodiazepines. In many, but not all of these cases, buprenorphine was misused by self-injection. Preclinical studies have shown that the combination of benzodiazepines and buprenorphine altered the usual clinical ceiling effect on buprenorphine-induced respiratory depression, making the respiratory effects of buprenorphine appear similar to those of full opioid agonists. BUNAVAIL buccal films should be prescribed with caution to patients taking benzodiazepines or other drugs that act on the CNS, regardless of whether these drugs are taken on the advice of a physician or are being abused/misused. Patients should be warned that it is extremely dangerous to self-administer non-prescribed benzodiazepines while taking BUNAVAIL buccal film, and should also be cautioned to use benzodiazepines concurrently with BUNAVAIL buccal films only as directed by their physician. Drug Abuse And Dependence Controlled Substance Buprenorphine is a Schedule III narcotic under the Controlled Substances Act. Under the Drug Addiction Treatment Act (DATA) codified at 21 U.S.C. 823(g), prescription use of this product in the treatment of opioid dependence is limited to physicians who meet certain qualifying requirements, and who have notified the Secretary of Health and Human Services (HHS) of their intent to prescribe this product for the treatment of opioid dependence and have been assigned a unique identification number that must be included on every prescription. Abuse Buprenorphine, like morphine and other opioids, has the potential for being abused and is subject to criminal diversion. This should be considered when prescribing or dispensing buprenorphine in situations when the clinician is concerned about an increased risk of misuse, abuse, or diversion. Healthcare professionals should contact their state professional licensing board or state controlled substances authority for information on how to prevent and detect abuse or diversion of this product. Patients who continue to misuse, abuse, or divert buprenorphine products or other opioids should be provided with, or referred to, more intensive and structured treatment. Abuse of buprenorphine poses a risk of overdose and death. This risk is increased with the abuse of buprenorphine and alcohol and other substances, especially benzodiazepines. The physician may be able to more easily detect misuse or diversion by maintaining records of medication prescribed including date, dose, quantity, frequency of refills, and renewal requests of medication prescribed. Proper assessment of the patient, proper prescribing practices, periodic re-evaluation of therapy, and proper handling and storage of the medication are appropriate measures that help to limit abuse of opioid drugs. Dependence Buprenorphine is a partial agonist at the mu-opioid receptor and chronic administration produces physical dependence of the opioid type, characterized by moderate withdrawal signs and symptoms upon abrupt discontinuation or rapid taper. The withdrawal syndrome is typically milder than seen with full agonists and may be delayed in onset [see WARNINGS AND PRECAUTIONS]. A neonatal withdrawal syndrome has been reported in the infants of women treated with buprenorphine during pregnancy [see WARNINGS AND PRECAUTIONS]. Last reviewed on RxList: 6/20/2014
This monograph has been modified to include the generic and brand name in many instances.
This monograph has been modified to include the generic and brand name in many instances.
Source: http://www.rxlist.com
BUNAVAIL buccal film is indicated for the maintenance treatment of opioid dependence and should be used as part of a complete treatment plan to include counseling and psychosocial support. Under the Drug Addiction Treatment Act (DATA) codified at 21 U.S.C. 823(g), prescription use of this product in the treatment of opioid dependence is limited to physicians who meet certain qualifying requirements, and who have notified the Secretary of Health and Human Services (HHS) of their intent to prescribe this product for the treatment of opioid dependence and have been assigned a unique identification number that must be included on every prescription.
Source: http://www.rxlist.com
BUNAVAIL buccal film should not be administered to patients who have been shown to be hypersensitive to buprenorphine or naloxone as serious adverse reactions, including anaphylactic shock, have been reported [see WARNINGS AND PRECAUTIONS]. Last reviewed on RxList: 6/20/2014
This monograph has been modified to include the generic and brand name in many instances.
This monograph has been modified to include the generic and brand name in many instances.
Source: http://www.rxlist.com
The manifestations of acute overdose include pinpoint pupils, sedation, hypotension, respiratory depression, and death. In the event of overdose, the respiratory and cardiac status of the patient should be monitored carefully. When respiratory or cardiac functions are depressed, primary attention should be given to the re-establishment of adequate respiratory exchange through provision of a patent airway and institution of assisted or controlled ventilation. Oxygen, IV fluids, vasopressors, and other supportive measures should be employed as indicated. In the case of overdose, the primary management should be the re-establishment of adequate ventilation with mechanical assistance of respiration, if required. Naloxone may be of value for the management of buprenorphine overdose. Higher than normal doses and repeated administration may be necessary. The long duration of action of BUNAVAIL should be taken into consideration when determining the length of treatment and medical surveillance needed to reverse the effects of an overdose. Insufficient duration of monitoring may put patients at risk.
Source: http://www.rxlist.com
Dosage Forms And Strengths BUNAVAIL buccal film is supplied as a yellow rectangular buccal film in three dosage strengths:
This monograph has been modified to include the generic and brand name in many instances.
- buprenorphine/naloxone 2.1 mg / 0.3 mg
- buprenorphine/naloxone 4.2 mg / 0.7 mg
- buprenorphine/naloxone 6.3 mg / 1 mg
This monograph has been modified to include the generic and brand name in many instances.
Source: http://www.rxlist.com
Abuse Potential Buprenorphine can be abused in a manner similar to other opioids, legal or illicit. Prescribe and dispense buprenorphine with appropriate precautions to minimize risk of misuse, abuse, or diversion, and ensure appropriate protection from theft, including in the home. Clinical monitoring appropriate to the patient's level of stability is essential. Multiple refills should not be prescribed early in treatment or without appropriate patient follow-up visits [see Drug Abuse and Dependence]. Respiratory Depression Buprenorphine, particularly when taken by the IV route, in combination with benzodiazepines or other CNS depressants (including alcohol), has been associated with significant respiratory depression and death. Many, but not all, post-marketing reports regarding coma and death associated with the concomitant use of buprenorphine and benzodiazepines involved misuse by self-injection. Deaths have also been reported in association with concomitant administration of buprenorphine with other depressants such as alcohol or other CNS depressant drugs. Patients should be warned of the potential danger of self-administration of benzodiazepines or other depressants while under treatment with BUNAVAIL buccal film [see DRUG INTERACTIONS]. In the case of overdose, the primary management should be the re-establishment of adequate ventilation with mechanical assistance of respiration, if required. Naloxone may be of value for the management of buprenorphine overdose. Higher than normal doses and repeated administration may be necessary. BUNAVAIL buccal film should be used with caution in patients with compromised respiratory function (e.g., chronic obstructive pulmonary disease, cor pulmonale, decreased respiratory reserve, hypoxia, hypercapnia, or pre-existing respiratory depression). CNS Depression Patients receiving buprenorphine in the presence of opioid analgesics, general anesthetics, benzodiazepines, phenothiazines, other tranquilizers, sedative/hypnotics, or other CNS depressants (including alcohol) may exhibit increased CNS depression. Consider dose reduction of CNS depressants, BUNAVAIL buccal film, or both in situations of concomitant prescription [see DRUG INTERACTIONS]. Unintentional Pediatric Exposure Buprenorphine can cause severe, possibly fatal, respiratory depression in children who are accidentally exposed to it. Store buprenorphine-containing medications safely out of the sight and reach of children and destroy any unused medication appropriately [see PATIENT INFORMATION]. Dependence Buprenorphine is a partial agonist at the mu-opioid receptor and chronic administration produces physical dependence of the opioid type, characterized by withdrawal signs and symptoms upon abrupt discontinuation or rapid taper. The withdrawal syndrome is typically milder than seen with full agonists and may be delayed in onset. Buprenorphine can be abused in a manner similar to other opioids. This should be considered when prescribing or dispensing buprenorphine in situations when the clinician is concerned about an increased risk of misuse, abuse, or diversion [see Drug Abuse and Dependence]. Hepatitis, Hepatic Events Cases of cytolytic hepatitis and hepatitis with jaundice have been observed in individuals receiving buprenorphine in clinical trials and through post-marketing adverse event reports. The spectrum of abnormalities ranges from transient asymptomatic elevations in hepatic transaminases to case reports of death, hepatic failure, hepatic necrosis, hepatorenal syndrome, and hepatic encephalopathy. In many cases, the presence of pre-existing liver enzyme abnormalities, infection with hepatitis B or hepatitis C virus, concomitant usage of other potentially hepatotoxic drugs, and ongoing injecting drug use may have played a causative or contributory role. In other cases, insufficient data were available to determine the etiology of the abnormality. Withdrawal of buprenorphine has resulted in amelioration of acute hepatitis in some cases; however, in other cases no dose reduction was necessary. The possibility exists that buprenorphine had a causative or contributory role in the development of the hepatic abnormality in some cases. Liver function tests, prior to initiation of treatment is recommended to establish a baseline. Periodic monitoring of liver function during treatment is also recommended. A biological and etiological evaluation is recommended when a hepatic event is suspected. Depending on the case, BUNAVAIL buccal film may need to be carefully discontinued to prevent withdrawal signs and symptoms and a return by the patient to illicit drug use, and strict monitoring of the patient should be initiated. Allergic Reactions Cases of hypersensitivity to buprenorphine and naloxone containing products have been reported both in clinical trials and in the post-marketing experience. Cases of bronchospasm, angioneurotic edema, and anaphylactic shock have been reported. The most common signs and symptoms include rashes, hives and pruritus. A history of hypersensitivity to buprenorphine or naloxone is a contraindication to the use of BUNAVAIL buccal film. Precipitation Of Opioid Withdrawal Signs And Symptoms Because it contains naloxone, BUNAVAIL buccal film is likely to produce withdrawal signs and symptoms if misused parenterally by individuals dependent on full opioid agonists such as heroin, morphine, or methadone. Because of the partial agonist properties of buprenorphine, BUNAVAIL buccal film may precipitate opioid withdrawal signs and symptoms in such persons if administered bucally before the agonist effects of the opioid have subsided. Neonatal Withdrawal Neonatal withdrawal has been reported in the infants of women treated with buprenorphine during pregnancy. From post-marketing reports, the time to onset of neonatal withdrawal signs ranged from Day 1 to Day 8 of life with most cases occurring on Day 1. Adverse events associated with the neonatal withdrawal syndrome included hypertonia, neonatal tremor, neonatal agitation, and myoclonus, and there have been reports of convulsions, apnea, respiratory depression, and bradycardia. Use In Opioid Naïve Patients There have been reported deaths of opioid naïve individuals who received a 2 mg dose of buprenorphine, smaller than the lowest strength of BUNAVAIL, for analgesia. BUNAVAIL buccal film is not appropriate as an analgesic. Use In Patients With Impaired Hepatic Function Buprenorphine/naloxone products are not recommended in patients with severe hepatic impairment and may not be appropriate for patients with moderate hepatic impairment. Because hepatic impairment results in a reduced clearance of naloxone to a much greater extent than buprenorphine, the doses of buprenorphine and naloxone in this fixed-dose combination product cannot be individually titrated. Therefore, patients with severe hepatic impairment will be exposed to substantially higher levels of naloxone than patients with normal hepatic function. This may result in an increased risk of precipitated withdrawal at the beginning of treatment (induction) and may interfere with buprenorphine's efficacy throughout treatment. In patients with moderate hepatic impairment, the differential reduction of naloxone clearance compared to buprenorphine clearance is not as great as in subjects with severe hepatic impairment. Therefore, buprenorphine/naloxone products are not recommended for initiation of treatment (induction) in patients with moderate hepatic impairment due to the increased risk of precipitated withdrawal. However, buprenorphine/naloxone products may be used with caution for maintenance treatment in patients with moderate hepatic impairment who have initiated treatment on a buprenorphine product without naloxone. However, patients should be carefully monitored and consideration given to the possibility of naloxone interfering with buprenorphine's efficacy [see Use In Specific Populations]. Impairment Of Ability To Drive Or Operate Machinery BUNAVAIL buccal film may impair the mental or physical abilities required for the performance of potentially dangerous tasks such as driving a car or operating machinery, especially during treatment induction and dose adjustment. Patients should be cautioned about driving or operating hazardous machinery until they are reasonably certain that BUNAVAIL buccal film therapy does not adversely affect his or her ability to engage in such activities. Orthostatic Hypotension Like other opioids, BUNAVAIL buccal film may produce orthostatic hypotension in ambulatory patients. Elevation Of Cerebrospinal Fluid Pressure Buprenorphine, like other opioids, may elevate cerebrospinal fluid pressure and should be used with caution in patients with head injury, intracranial lesions, and other circumstances when cerebrospinal pressure may be increased. Buprenorphine can produce miosis and changes in the level of consciousness that may interfere with patient evaluation. Elevation Of Intracholedochal Pressure Buprenorphine has been shown to increase intracholedochal pressure, as do other opioids, and thus should be administered with caution to patients with dysfunction of the biliary tract. Effects In Acute Abdominal Conditions As with other opioids, buprenorphine may obscure the diagnosis or clinical course of patients with acute abdominal conditions. General Precautions BUNAVAIL buccal film should be administered with caution in debilitated patients and those with myxedema or hypothyroidism, adrenal cortical insufficiency (e.g., Addison's disease); CNS depression or coma; toxic psychoses; prostatic hypertrophy or urethral stricture; acute alcoholism; delirium tremens; or kyphoscoliosis. Patient Counseling Information See FDA approved patient labeling (Medication Guide). Safe Use Before initiating treatment with BUNAVAIL buccal film, explain the points listed below to caregivers and patients. Instruct patients to read the Medication Guide each time BUNAVAIL is dispensed because new information may be available
This monograph has been modified to include the generic and brand name in many instances.
- Patients should be warned that it is extremely dangerous to self-administer non-prescribed benzodiazepines or other CNS depressants (including alcohol) while taking BUNAVAIL buccal films. Patients prescribed benzodiazepines or other CNS depressants should be cautioned to use them only as directed by their physician [see WARNINGS AND PRECAUTIONS, DRUG INTERACTIONS].
- Patients should be advised that BUNAVAIL buccal films contain an opioid that can be a target for people who abuse prescription medications or street drugs. Patients should be cautioned to keep their films in a safe place, and to protect them from theft.
- Patients should be instructed to keep BUNAVAIL buccal films in a secure place, out of the sight and reach of children. Accidental or deliberate ingestion by a child may cause respiratory depression that can result in death. Patients should be advised that if a child is exposed to BUNAVAIL buccal films, medical attention should be sought immediately.
- Patients should be advised never to give BUNAVAIL buccal films to anyone else, even if he or she has the same signs and symptoms. It may cause harm or death.
- Patients should be advised that selling or giving away this medication is against the law.
- Patients should be cautioned that BUNAVAIL buccal films may impair the mental or physical abilities required for the performance of potentially dangerous tasks such as driving or operating machinery. Caution should be taken especially during drug induction and dose adjustment and until individuals are reasonably certain that buprenorphine therapy does not adversely affect their ability to engage in such activities [see WARNINGS AND PRECAUTIONS].
- Patients should be advised not to change the dosage of BUNAVAIL buccal films without consulting their physician.
- Patients should be advised to take BUNAVAIL buccal films once a day.
- Patients should be informed that BUNAVAIL buccal films can cause drug dependence and that withdrawal signs and symptoms may occur when the medication is discontinued.
- Patients should be cautioned that, like other opioids, BUNAVAIL may produce orthostatic hypotension in ambulatory individuals.
- Patients seeking to discontinue treatment with buprenorphine for opioid dependence should be advised to work closely with their physician on a tapering schedule and should be apprised of the potential to relapse to illicit drug use associated with discontinuation of opioid agonist/partial agonist medication-assisted treatment.
- Patients should inform their physician if any other prescription medications, over-the-counter medications, or herbal preparations are prescribed or currently being used [see DRUG INTERACTIONS].
- Women of childbearing potential, who become pregnant or are planning to become pregnant, should be advised to consult their physician regarding the possible effects of using BUNAVAIL buccal films during pregnancy [see Use In Specific Populations].
- Patients should be warned that buprenorphine passes into breast milk. Advise women who are breastfeeding to monitor the infant for drowsiness and difficulty breathing [see Use In Specific Populations].
- Patients should inform their family members that, in the event of emergency, the treating physician or emergency room staff should be informed that the patient is physically dependent on an opioid and that the patient is being treated with BUNAVAIL buccal films.
- Patients should be advised that if they miss a dose of BUNAVAIL they should take it as soon as they remember. If it is almost time for the next dose, they should skip the missed dose and take the next dose at the regular time.
- Refer to the Medication Guide for additional information regarding the counseling information.
- Remove the BUNAVAIL film from its foil package.
- Drop the BUNAVAIL film into the toilet.
- Repeat steps 1 and 2 for each BUNAVAIL film. Flush the toilet after all unneeded films have been deposited into the toilet.
This monograph has been modified to include the generic and brand name in many instances.
Source: http://www.rxlist.com
Search Symptoms, Conditions,
and Medications
Powered by: WebHealthNetwork
Medications Related to Vaccine
Aggregated Health News & Articles
Join Millions
Sign Up For One Of Our
Newsletters
Drug Database Online
Welcome to Vaccine Health Center an online drug guide and dictionary, here you can get drug information and definitaions for most popular pharmaceutical and medicinal drugs, and specifically Bunavail. Find what medications you are taking today.